July’s Molecules on the Move
In May 2024, major transactions advanced neuroplastogens, KRAS G12C inhibitors, Pompe disease treatments, and molecular glues. Positive clinical readouts were seen for TTR stabilizers, Hedgehog pathway inhibitors, plasma kallikrein inhibitors, DPP-1 inhibitors, and PCSK9 inhibitors.
Highlighted Terms
Related News
July’s Molecules on the Move
In May 2024, major transactions advanced neuroplastogens, KRAS G12C inhibitors, Pompe disease treatments, and molecular glues. Positive clinical readouts were seen for TTR stabilizers, Hedgehog pathway inhibitors, plasma kallikrein inhibitors, DPP-1 inhibitors, and PCSK9 inhibitors.